PIK3CA and hepatocellular carcinoma: On the other hand, treatment with sorafenib in HCC cells elicited heterogeneous inhibitions of ERK1/2 (MAPK) and RPS6 (S6) phosphorylation (PI3K/mTOR) alongside a consistent activation of P-AMPK between cell lines (Supplementary Table 5).